Semaglutide
GLP-1 Receptor Agonist Modified Polypeptide
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist modified with an alpha-aminoisobutyric acid substitution and a C-18 fatty diacid spacer to facilitate non-covalent albumin binding. Characterized across human clinical trials for glucose regulation and neuro-endocrine appetite pathway interactions.
Indexed for laboratory in vitro receptor binding assays and cellular synthesis research. Commercial materials are procured as non-clinical reagents under verified laboratory standards.
Chemical Structure & Metrics
Structured Chemical & Preclinical Profile
1. Chemical Identity & Sequence Architecture
Semaglutide (GLP-1 Receptor Agonist Modified Polypeptide) is an analytically characterized peptide with empirical formula C187H291N45O59 (MW 4113.6 g/mol). CAS Registry: 910463-68-2.
2. Primary Preclinical Signaling Axis
Investigated in preclinical assays for cellular signaling: Selective agonism of GLP-1 receptors in the pancreas and central nervous system nuclei.
3. Physical Formats & Delivery Matrices
Synthesized predominantly as high-purity lyophilized powder cakes, with secondary pre-metered pen cartridges and solution atomizers cataloged across vendors.
4. Reconstitution & Analytical Handling
Recommended reconstitution with Bacteriostatic 0.9% Benzyl Alcohol USP or Sterile Diluent. Lyophilized cake stored at -20°C desiccated (stable up to 24 months). Solution stable at 2°C to 8°C refrigerated (stable 28 days).
Signaling Pathways & Laboratory Handling Protocols
Documented Receptor Pathways & In Vitro Signaling
Selective agonism of GLP-1 receptors in the pancreas and central nervous system nuclei.
Stimulation of glucose-dependent insulin biosynthesis and suppression of inappropriate glucagon secretion.
Modulation of pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus.
Deceleration of gastric motility and regulation of peripheral glycemic excursion profiles.
Evaluated across global clinical trial programs (SUSTAIN and STEP) and in vitro incretin signaling assays.
Handling Parameters
Peptide Dilution & Reconstitution Calculator
Compute stock concentrations, micro-pipetting draw volumes, and U-100 syringe units with zero procedural guesswork.
Slowly introduce bacteriostatic diluent against the internal glass vial wall. Swirl gently in a circular horizontal rotation. Never shake or vortex vigorously to prevent mechanical shearing of delicate peptide bonds. Store reconstituted stock at 2°C–8°C.
Partner & Vendor Catalogues for Semaglutide
Independent partner directory providing research-grade lyophilized vials, cartridges, atomizers, and reconstitution solvents.
Category hub featuring research-grade lyophilized vials, pens, and blends.
Full catalogue category hub with multiple mg vial sizes and blends.
Dedicated category hub listing research vials and cartridges.
UK-stocked research reagent catalogue hub featuring batch-verified peptide lots.
Global catalogue hub including international dispatch batches.
Academic Bibliography & Preclinical Studies for Semaglutide
Primary academic indexing sourced from PubMed and peer-reviewed biotechnology journals documenting molecular mechanisms and in vitro cellular response.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Frequently Asked Chemical & Analytical Questions
Authoritative scientific clarifications regarding Semaglutide classification, molecular pathways, and laboratory protocols.
Semaglutide (GLP-1 Receptor Agonist Modified Polypeptide) is an analytically characterized peptide compound with empirical molecular formula C187H291N45O59 and molecular weight 4113.6 g/mol. It is indexed under CAS Registry Number 910463-68-2 and categorized in research literature under Metabolic & Incretin Signaling.